Press Releases

;

Job Announcement: Government Affairs Manager

Nov 6, 2023

The HIV+Hepatitis Policy Institute is a national 501(c)(3) non-profit organization incorporated in the District of Columbia whose mission is to promote quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions. We are seeking a Government Affairs Manager to advocate for our policy goals to end the HIV and hepatitis epidemics and increase access and affordability of healthcare with a focus on prescription drugs. 

read more

From the office of Massachusetts Senate President Karen E. Spilka: Senate passes bill expanding access to HIV prevention drug

Oct 27, 2023

“For the first time since PrEP became available eleven years ago, over a third of the people CDC believes could benefit from being on PrEP are being prescribed it. However, there are stark and widening racial, ethnic, and gender disparities in PrEP use in Massachusetts and nationwide,” said Kevin Herwig, Health Policy Manager at HIV+Hepatitis Policy Institute. “Allowing pharmacists to prescribe PrEP, as well as to link people with PrEP clinical services and HIV testing, will help remove barriers to getting HIV preventive medication for people and communities who have not yet been able to benefit from the promise of PrEP.  We thank the Senate, Senate President Spilka, Senator Cyr, and others for supporting this important legislation.”

read more

New CDC PrEP data demonstrates importance of federal funding

Oct 17, 2023

“While the data demonstrate progress in PrEP usage, which will translate into fewer new HIV transmissions, the low usage of PrEP among the communities most impacted by HIV points to the need for increased and targeted federal resources,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “Unfortunately, House Republicans have proposed to cut $220 million from CDC’s HIV prevention program and completely eliminate HRSA’s $157 million PrEP program for community health centers. If these cuts were to be realized, instead of reporting on progress, the nation will be experiencing increased new HIV transmissions, which in the long run will cost us more.”

read more

Court strikes down HHS rule that allowed insurers to not count copay assistance

Oct 2, 2023

In a major victory for patients who depend on prescription drugs, Judge John D. Bates of the U.S. District Court for the District of Columbia struck down a Trump administration federal rule that allowed health insurers to not count drug manufacturer copay assistance towards a beneficiary’s out-of-pocket costs. The case was brought against the U.S. Department of Health and Human Services by the HIV+Hepatitis Policy Institute, Diabetes Leadership Council, Diabetes Patient Advocacy Coalition, and three patients who depend on copay assistance and whose insurers implemented “copay accumulator” policies.

read more

HIV+Hep alleges Texas health plan providing substandard & discriminatory HIV drug coverage

Sep 26, 2023

Today, the HIV+Hepatitis Policy Institute filed another complaint against an insurer for violating the patient protections included in the Affordable Care Act. This time, the group alleges that Community Health Choice Texas, based in Houston, offers substandard HIV drug coverage by not covering recommended drugs for HIV treatment, including single tablet regimens, and is discriminating against people with HIV by placing most of the drugs that it does cover on the highest and most costly tier.

read more

Search

Press Release Tags

ACA Appropriations Biden administration CDC Congress Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B Hepatitis C hepatits HIV HIV Prevention hous housing insurer Insurers LGBT Medicaid Medicare Part D NAIC NIH PBMs PrEP Prescription Drugs prevention Private Insurance Ryan White Ryan White Program state Syringe services Testing transparency Treatment Trump administration

Recent Press Releases

Pin It on Pinterest